Leerink raises Encompass Health stock price target on growth outlook

Leerink raised its price target on Encompass Health to $152 from $138 while reiterating an Outperform rating, citing historically high bed additions, de novo facilities, and 15% ROIC over the latest twelve months. The company also priced a $500 million senior notes deal due 2034 at 5.875% and declared a quarterly dividend of $0.19 per share. Management commentary and recent Truist confirmation of a Buy rating reinforce a positive revision path, though some guidance implies higher unit costs.

Analysis

The market is still pricing EHC like a mature, low-growth operator, but the combination of de novo capacity, higher bed additions, and easing controversy creates a setup where earnings revisions can compound faster than the multiple can normalize. The key second-order effect is that incremental beds in rehab are not just revenue adds; they improve fixed-cost absorption across a network with meaningful operating leverage, so small utilization surprises can drive outsized EBITDA revisions over the next 2-3 quarters.

The debt deal matters because it removes a financing overhang at a time when the company is still proving it can self-fund expansion. A 2034 maturity pushes refinancing risk far out, but the near-term signal is that management is comfortable layering in long-duration capital while the business is still in a positive unit-growth phase; that usually tightens the stock’s discount rate if execution holds. The dividend reinforces that this is no longer being treated as a pure reinvestment story, which can attract a different shareholder base and support a re-rating over the next 6-12 months.

The contrarian issue is that consensus may be underestimating how much of the bullish case is already tied to continued benign reimbursement, labor, and bad-debt trends. If any one of those turns, the market will likely de-rate the name quickly because the current multiple still implies skepticism about durability. But if the company keeps printing above-guidance EBITDA while opening beds on schedule, the path to a 12x-13x earnings multiple is plausible, which is meaningfully above current levels and leaves room for another leg up before year-end.

Key Decisions for Investors

• Go long EHC on any post-rally consolidation, targeting a 3-6 month hold; upside is driven by multiple expansion plus operating leverage, with downside contained if execution stays on track.
• Buy EHC Jan-2027 call spreads to express the re-rating thesis with defined risk; this is better than stock ownership if the market remains skeptical on reimbursement and cost durability.
• Pair long EHC / short a lower-quality, slower-growing post-acute or rehab peer over the next 2-4 quarters; the relative value case is strongest if EHC continues outperforming on unit growth and cash flow conversion.
• Use the recent notes issuance as a monitoring trigger: if credit spreads widen or the stock fails to respond after the next quarter, reduce exposure, since the market may be signaling concern about capex intensity or marginal growth economics.